Ushio Noritaka, Wada Takeshi, Ono Yuichiro, Yamakawa Kazuma
Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine Hokkaido University Faculty of Medicine Sapporo Japan.
Acute Med Surg. 2023 May 4;10(1):e00843. doi: 10.1002/ams2.843. eCollection 2023 Jan-Dec.
Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by widespread intravascular activation of coagulation, which can be caused by infectious and noninfectious insults, such as trauma, postcardiac arrest syndrome, and malignant diseases. At present, diagnosis and treatment of DIC clearly differ between Japan and Western countries; in Japan, DIC has long been considered a therapeutic target, and much evidence on DIC has been published. However, there has recently been no international consensus on whether DIC should be a therapeutic target with anticoagulant therapy. This review describes the coagulofibrinolytic system abnormalities associated with sepsis and discusses related management strategies. It also explores the reasons why DIC is perceived differently in different regions. There is a major discrepancy between diagnostic and treatment options in Japan, which are based on holistic assessments of trials, as well as the results of post hoc subgroup analyses and observational studies, and those in Western countries, which are based mainly on the results of sepsis mega trials, especially randomized controlled trials. The differences might also be due to various patient factors in each region, especially racial characteristics in thrombolytic mechanisms, and differences in interpretation of evidence for candidate drugs. Hence, Japanese researchers need to distribute their high-quality clinical research data not only to Japan but also to the rest of the world.
弥散性血管内凝血(DIC)是一种获得性综合征,其特征为广泛的血管内凝血激活,可由感染性和非感染性损伤引起,如创伤、心脏骤停后综合征和恶性疾病。目前,日本和西方国家对DIC的诊断和治疗明显不同;在日本,DIC长期以来一直被视为治疗靶点,并且已经发表了许多关于DIC的证据。然而,最近对于DIC是否应作为抗凝治疗的靶点尚未达成国际共识。本综述描述了与脓毒症相关的凝血纤溶系统异常,并讨论了相关的管理策略。它还探讨了不同地区对DIC认知不同的原因。日本基于试验的整体评估以及事后亚组分析和观察性研究的结果,与西方国家主要基于脓毒症大型试验尤其是随机对照试验的结果之间,在诊断和治疗选择上存在重大差异。这些差异也可能归因于每个地区的各种患者因素,特别是溶栓机制中的种族特征,以及对候选药物证据解释的差异。因此,日本研究人员不仅需要将其高质量的临床研究数据在日本国内传播,还需要传播到世界其他地区。